Dergiler / Haydarpaşa Numune Medical Journal / 2022 / Cilt: 62 - Sayı: 2

Evaluation of Clinical Outcomes of a Cohesive Ophthalmic Viscosurgical Device

Sayfa
195–199
Yayın Tarihi
2022-10-19
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Discussion and Conclusion: BIO-HYALUR Plus OVD cohesive properties and was safe and effective for every stage of cataract surgery without additional toxicity nor result in increased endothelial cell loss.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Introduction: To evaluate, the clinical outcomes in patients undergoing cataract surgery with use of sodium hyaluronate 1.4% for its ability to maintain anterior chamber space and protection of corneal endothelial cells.
📊
Temel Bulgular & Veri:A total 52 patients (eyes) having age older than 45 years with Grade I to III cataract were enrolled in the study and BIO-HYALUR Plus was used as ophthalmic viscosurgical device (OVD) during the standard cataract surgery procedure.
💡
Sonuç & Katkı:Discussion and Conclusion: BIO-HYALUR Plus OVD cohesive properties and was safe and effective for every stage of cataract surgery without additional toxicity nor result in increased endothelial cell loss.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Introduction: To evaluate, the clinical outcomes in patients undergoing cataract surgery with use of sodium hyaluronate 1.4% for its ability to maintain anterior chamber space and protection of corneal endothelial cells. Methods: This was a single center, retrospective observational study. A total 52 patients (eyes) having age older than 45 years with Grade I to III cataract were enrolled in the study and BIO-HYALUR Plus was used as ophthalmic viscosurgical device (OVD) during the standard cataract surgery procedure. Pre-operative and post-operative day 1, 1 week, 1 month, and 3 months visits, data assessments included: Adverse events observed during the study were also noted for the evaluation of safety. Results: Intraoperative anterior chamber space maintenance has been well formed for all 52 (100%) patients (eyes). Corneal clarity was observed for all patients. At 3-month follow-up visit, the mean best-corrected visual acuity was improved to 0.9±0.17 (Snellen Decimal). There was decreased in mean ECC, cell density, intraocular pressure, corneal thickness, coefficient of variance in cell size, and cell area compare to pre-operative visits on follow-up period. No adverse events were reported during entire study. Discussion and Conclusion: BIO-HYALUR Plus OVD cohesive properties and was safe and effective for every stage of cataract surgery without additional toxicity nor result in increased endothelial cell loss.

🔖

Bu Makaleye Atıf Yap

ÇELİK, N. B., ÇELİK, H. U., SEVİM, M. Ş. (2022). Evaluation of Clinical Outcomes of a Cohesive Ophthalmic Viscosurgical Device. Haydarpaşa Numune Medical Journal, Cilt: 62 - Sayı: 2, 195–199. https://ajindex.com/articles/535834

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Benjamin L. Fluidics and rheology in phaco surgery: What matters and what is the hype? Eye (Lond) 2018;32:204–9
  2. Tognetto D, Cecchini P, Ravalico G. Survey of ophthalmic viscosurgical devices. Curr Opin Ophthalmol 2004;15:29–32
  3. Modi SS, Davison JA, Walters T. Safety, efficacy, and intraoperative characteristics of DisCoVisc and Healon ophthalmic viscosurgical devices for cataract surgery. Clin Ophthalmol 2011;5:1381–9
  4. Arshinoff SA, Jafari M. New classification of ophthalmic viscosurgical devices--2005. J Cataract Refract Surg 2005;31:2167– 71
  5. Balazs EA. Use of hyaluronic acid in eye surgery. Annee Ther Clin Ophtalmol 1982;33:95–110. [Article in French] 6. Pandey S, Thakur J, Werner L, Izak A, Apple D. Update on ophthalmic viscosurgical devices. In: Agarwal S, Agarwal A, Agarwal A, editors. Phacoemulsification. 3rd ed. Boca Raton, FL: Taylor and Francis; 2004. p.179–95
  6. Bissen-Miyajima H. Ophthalmic viscosurgical devices. Curr Opin Ophthalmol 2008;19:50–4
  7. Miller KM, Colvard DM. Randomized clinical comparison of Healon GV and Viscoat. J Cataract Refract Surg 1999;25:1630– 6
  8. Tetz MR, Holzer MP, Lundberg K, Auffarth GU, Burk RO, Kruse FE. Clinical results of phacoemulsification with the use of Healon5 or Viscoat. J Cataract Refract Surg 2001;27:416–20
  9. Holzer MP, Tetz MR, Auffarth GU, Welt R, Völcker HE. Effect of Healon5 and 4 other viscoelastic substances on intraocular pressure and endothelium after cataract surgery. J Cataract Refract Surg 2001;27:213–8
  10. Takahashi H, Sakamoto A, Takahashi R, Ohmura T, Shimmura S, Ohara K. Free radicals in phacoemulsification and aspiration procedures. Arch Ophthalmol 2002;120:1348–52
  11. Maugeri F, Maltese A, Ward KW, Bucolo C. Hydroxyl radical scavenging activity of a new ophthalmic viscosurgical device. Curr Eye Res 2007;32:105–11
  12. Assia EI, Apple DJ, Lim ES, Morgan RC, Tsai JC. Removal of viscoelastic materials after experimental cataract surgery in vitro. J Cataract Refract Surg 1992;18:3–6
  13. Modi SS, Davison JA, Walters T. Safety, efficacy, and intraoperative characteristics of DisCoVisc and Healon ophthalmic viscosurgical devices for cataract surgery. Clin Ophthalmol 2011;5:1381–9
  14. Bourne WM, McLaren JW. Clinical responses of the corneal endothelium. Exp Eye Res 2004;78:561–72
  15. Glasser DB, Osborn DC, Nordeen JF, Min YI. Endothelial protection and viscoelastic retention during phacoemulsification and intraocular lens implantation. Arch Ophthalmol 1991;109:1